Drugmaker GSK has agreed to acquire Canadian clinical-stage biopharmaceutical firm 35Pharma for $950m in cash.
GSK
25 February 2026 07:32:44
Source: Sharecast
GSK said on Wednesday that the acquisition includes 35Pharma's HS235, a potential best-in-class investigational medicine that has completed phase I healthy volunteer clinical trials, with studies to start imminently in pulmonary arterial hypertension and pulmonary hypertension due to heart failure with preserved ejection fraction.
The FTSE 100-listed firm noted that the global market for PH therapies was forecast to reach $18bn by 2032, with activin signalling inhibitors expected to account for 50% of this.
GSK added that transaction was subject to customary conditions, including applicable regulatory agency clearances under the Hart-Scott-Rodino Act in the US and the Competition Act in Canada, along with a filing under the Investment Canada Act.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
